202 related articles for article (PubMed ID: 37008735)
1. Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast cancer immunotherapy.
Zhang H; Chen L; Zhao Y; Luo N; Shi J; Xu S; Ma L; Wang M; Gu M; Mu C; Xiong Y
Asian J Pharm Sci; 2023 Mar; 18(2):100796. PubMed ID: 37008735
[TBL] [Abstract][Full Text] [Related]
2. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
3. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
4. Rhein potentiates doxorubicin in treating triple negative breast cancer by inhibiting cancer-associated fibroblasts.
Xu S; Zheng S; Ma N; Zhang H; Shi J; Huang J; Luo N; Wang M; Xiong Y
Biochem Pharmacol; 2024 May; 223():116139. PubMed ID: 38499109
[TBL] [Abstract][Full Text] [Related]
5. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
6. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
7. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
8. Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency.
Wu Y; Chen R; Ni S; Hu K
J Control Release; 2024 Jun; 370():556-569. PubMed ID: 38697316
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model.
Rahman A; Janic B; Rahman T; Singh H; Ali H; Rattan R; Kazi M; Ali MM
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894298
[TBL] [Abstract][Full Text] [Related]
10. Safe engineering of cancer-associated fibroblasts enhances checkpoint blockade immunotherapy.
Geng S; Xiang T; Zhang Y; Guo P; Zhang H; Zhang Z; Gu M; Zhang K; Song H; Shi J; Liu J
J Control Release; 2023 Apr; 356():272-287. PubMed ID: 36870541
[TBL] [Abstract][Full Text] [Related]
11. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
12. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
13. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
[TBL] [Abstract][Full Text] [Related]
14. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
15. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming by dual-targeting biomimetic nanoparticles for enhanced tumor chemo-immunotherapy.
Zang S; Huang K; Li J; Ren K; Li T; He X; Tao Y; He J; Dong Z; Li M; He Q
Acta Biomater; 2022 Aug; 148():181-193. PubMed ID: 35649505
[TBL] [Abstract][Full Text] [Related]
17. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.
Wu Y; Yi Z; Li J; Wei Y; Feng R; Liu J; Huang J; Chen Y; Wang X; Sun J; Yin X; Li Y; Wan J; Zhang L; Huang J; Du H; Wang X; Li Q; Ren G; Li H
Theranostics; 2022; 12(10):4564-4580. PubMed ID: 35832090
[No Abstract] [Full Text] [Related]
18. Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy.
Zhang H; Yu J; Ma L; Zhao Y; Xu S; Shi J; Qian K; Gu M; Tan H; Xu L; Liu Y; Mu C; Xiong Y
Int J Pharm; 2022 Aug; 624():121931. PubMed ID: 35750278
[TBL] [Abstract][Full Text] [Related]
19. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.
Pei L; Liu Y; Liu L; Gao S; Gao X; Feng Y; Sun Z; Zhang Y; Wang C
Mol Cancer; 2023 Feb; 22(1):29. PubMed ID: 36759842
[TBL] [Abstract][Full Text] [Related]
20. Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer.
Zheng S; Zou Y; Tang Y; Yang A; Liang JY; Wu L; Tian W; Xiao W; Xie X; Yang L; Xie J; Wei W; Xie X
Oncoimmunology; 2022; 11(1):2020984. PubMed ID: 35003899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
